[
  {
    "ts": null,
    "headline": "Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy",
    "summary": "FOSTER CITY, Calif., February 25, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The",
    "url": "https://finnhub.io/api/news?id=951904e0f09a0b2fcbf372bba867f7a661c693e73bc26802b07160532af77b7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772045040,
      "headline": "Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy",
      "id": 139224006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., February 25, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The",
      "url": "https://finnhub.io/api/news?id=951904e0f09a0b2fcbf372bba867f7a661c693e73bc26802b07160532af77b7d"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
    "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
    "url": "https://finnhub.io/api/news?id=8f89cc05824cb2ac825f2a3f542aad6335186195d3777aab1741548f68c0dc95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772041080,
      "headline": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
      "id": 139223955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
      "url": "https://finnhub.io/api/news?id=8f89cc05824cb2ac825f2a3f542aad6335186195d3777aab1741548f68c0dc95"
    }
  },
  {
    "ts": null,
    "headline": "2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question",
    "summary": "The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.",
    "url": "https://finnhub.io/api/news?id=78595f5b841f0e58952a115b423a66c2ea3b60c12e377911261aa70615bcb499",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772021495,
      "headline": "2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question",
      "id": 139207529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.",
      "url": "https://finnhub.io/api/news?id=78595f5b841f0e58952a115b423a66c2ea3b60c12e377911261aa70615bcb499"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy",
    "summary": "Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash.",
    "url": "https://finnhub.io/api/news?id=cc93cecf3d72652fdbe30fda7cc9d8b0fc940b8b1ce3af9a17bc013dbaf0bcc6",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772017779,
      "headline": "Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy",
      "id": 139209933,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/25/Feb-19--2020-Foster-City-----Ca-----Usa-.jpeg?width=2048&height=1536",
      "related": "GILD",
      "source": "Benzinga",
      "summary": "Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash.",
      "url": "https://finnhub.io/api/news?id=cc93cecf3d72652fdbe30fda7cc9d8b0fc940b8b1ce3af9a17bc013dbaf0bcc6"
    }
  },
  {
    "ts": null,
    "headline": "2026 CNBC Changemakers: Women leaders who defied the odds to reach the highest levels of success",
    "summary": "The 2026 CNBC Changemakers are women defying the odds to reach the highest levels of success in fields from AI to healthcare, retail, sports and entertainment.",
    "url": "https://finnhub.io/api/news?id=489d787a06f742964be701d780d93287e536358b389d5faf3a4af2b2930a742c",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771999260,
      "headline": "2026 CNBC Changemakers: Women leaders who defied the odds to reach the highest levels of success",
      "id": 139212180,
      "image": "https://image.cnbcfm.com/api/v1/image/108268496-1771857893709-gettyimages-2236997251-68cc649891089d6534d7c56f.jpeg?v=1771857923&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "The 2026 CNBC Changemakers are women defying the odds to reach the highest levels of success in fields from AI to healthcare, retail, sports and entertainment.",
      "url": "https://finnhub.io/api/news?id=489d787a06f742964be701d780d93287e536358b389d5faf3a4af2b2930a742c"
    }
  },
  {
    "ts": null,
    "headline": "These 4 charts show the scale of Novo Nordisk's woes",
    "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
    "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771997562,
      "headline": "These 4 charts show the scale of Novo Nordisk's woes",
      "id": 139212445,
      "image": "https://image.cnbcfm.com/api/v1/image/108245068-1766477256303-gettyimages-2228673815-raa-novonord250809_npj4Z.jpeg?v=1768247892&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.",
      "url": "https://finnhub.io/api/news?id=16985f75739012f9804d2c8eecc059bddaf431662a1b6197fe1e120314a3474f"
    }
  },
  {
    "ts": null,
    "headline": "CNBC's UK Exchange newsletter: With shares up 1,200%, Rolls-Royce’s CEO has lots to shout about",
    "summary": "As with its aircraft engines, there are a lot of moving parts to Rolls-Royce — not least in some of its newest ventures.",
    "url": "https://finnhub.io/api/news?id=3c2abcda601d550a1bea45199359cb616315a07471654c7f63603a52db56ba7b",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771983794,
      "headline": "CNBC's UK Exchange newsletter: With shares up 1,200%, Rolls-Royce’s CEO has lots to shout about",
      "id": 139212391,
      "image": "https://image.cnbcfm.com/api/v1/image/103162015-RR.jpg?v=1532564227&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "As with its aircraft engines, there are a lot of moving parts to Rolls-Royce — not least in some of its newest ventures.",
      "url": "https://finnhub.io/api/news?id=3c2abcda601d550a1bea45199359cb616315a07471654c7f63603a52db56ba7b"
    }
  }
]